Copyright ©The Author(s) 2015.
World J Hepatol. May 8, 2015; 7(7): 980-992
Published online May 8, 2015. doi: 10.4254/wjh.v7.i7.980
Table 1 Information of clinical trials of checkpoint blockade on hepatocellular carcinoma after 2008
InterventionsDesignStart yearMain inclusion criteriaPrimary outcomesRegistered No.Status
CP-675,206: anti-CTLA-4 antibodyPhase II2008Unresectable disease not amenable to loco regional treatment, HCV chronic infectionTumor responseNCT01008358Completed
CT-011 (Pidilizumab): anti-PD-1 antibodyPhase I/II2009HCC not eligible for surgery, TACE, or other systematic treatmentsSafety and tolerabilityNCT00966251Terminated because of slow accrual
Nivolumab: anti-PD-1 antibodyPhase I2012Advanced HCC, failed in previous one line therapyAdverse eventsNCT01658878Recruiting
Tremelimumab: anti-CTLA-4 antibody, combined with TACE or RFAPhase I2013Not amenable to curative resection, transplantation or ablationSafety and feasibilityNCT01853618Recruiting